Recordati Rare Drug Patent Portfolio
Recordati Rare owns 4 orange book drugs protected by 15 US patents Given below is the list of Recordati Rare's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10709691 | Pharmaceutical dosage forms | 12 Oct, 2035 | Active |
| US10143680 | Pharmaceutical dosage forms | 06 Jul, 2035 | Active |
| US8415337 | Ibuprofen compositions and methods of making same | 02 Mar, 2032 | Active |
| US8609862 | Use of an adrenal hormone-modifying agent | 13 Jan, 2031 | Active |
| US9434754 | Use of an adrenal hormone-modifying agent | 13 Jan, 2031 | Active |
| US8314097 | Organic compounds | 27 Mar, 2029 | Active |
| US9351923 | Extended-release composition comprising a somatostatin derivative in microparticles | 23 May, 2028 | Active |
| US7473761 | Somatostatin analogues | 14 Dec, 2026 | Active |
| US7759308 | Microparticles comprising somatostatin analogues | 25 Oct, 2026 | Active |
| US8835646 | Organic compounds | 23 Aug, 2026 | Active |
| US8299209 | Pharmaceutical composition comprising cyclic somatostatin analogues | 27 Dec, 2025 | Active |
| US8822637 | Somatostatin analogues | 06 Aug, 2023 | Expired |
| US6344479 | Method of preventing retinopathy of prematurity in a neonate | 20 Mar, 2021 | Expired |
| US6342530 | Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt | 14 Nov, 2020 | Expired |
| US6225284 | Somatostatin peptides | 28 Jun, 2016 | Expired |
Latest Legal Activities on Recordati Rare's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Recordati Rare.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 May, 2024 | US8314097 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Apr, 2024 | US8299209 |
|
Email Notification
Critical
| 13 Mar, 2024 | US9434754 |
| Recordation of Patent eCertificate of Correction | 12 Mar, 2024 | US9434754 |
| Patent eCofC Notification | 12 Mar, 2024 | US9434754 |
| Mail Patent eCofC Notification | 12 Mar, 2024 | US9434754 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Mar, 2024 | US9434754 |
| Court Processing Terminated | 01 Mar, 2024 | US7473761 |
| Court Processing Terminated | 01 Mar, 2024 | US7473761 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8314097 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8609862 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US8609862 |
| transaction for FDA Determination of Regulatory Review Period | 23 Feb, 2024 | US8314097 |
| Post Issue Communication - Certificate of Correction | 22 Feb, 2024 | US9434754 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Jan, 2024 | US10709691 |
Recordati Rare's Family Patents
Recordati Rare Drug List
Given below is the complete list of Recordati Rare's drugs and the patents protecting them.
1. Isturisa
Isturisa is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10709691 | Pharmaceutical dosage forms |
12 Oct, 2035
(10 years from now)
| Active |
| US10143680 | Pharmaceutical dosage forms |
06 Jul, 2035
(10 years from now)
| Active |
| US8609862 | Use of an adrenal hormone-modifying agent |
13 Jan, 2031
(6 years from now)
| Active |
| US9434754 | Use of an adrenal hormone-modifying agent |
13 Jan, 2031
(6 years from now)
| Active |
| US8314097 | Organic compounds |
27 Mar, 2029
(4 years from now)
| Active |
| US8835646 | Organic compounds |
23 Aug, 2026
(1 year, 8 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Isturisa's drug page
2. Neoprofen
Neoprofen is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8415337 | Ibuprofen compositions and methods of making same |
02 Mar, 2032
(7 years from now)
| Active |
| US6344479 | Method of preventing retinopathy of prematurity in a neonate |
20 Mar, 2021
(3 years ago)
| Expired |
| US6342530 | Composition and method for parenteral administration of ibuprofen d,l- or l-lysine salt |
14 Nov, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Neoprofen's drug page
3. Signifor
Signifor is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7473761 | Somatostatin analogues |
14 Dec, 2026
(1 year, 11 months from now)
| Active |
| US8299209 | Pharmaceutical composition comprising cyclic somatostatin analogues |
27 Dec, 2025
(1 year, 8 days from now)
| Active |
| US6225284 | Somatostatin peptides |
28 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Signifor's drug page
4. Signifor Lar Kit
Signifor Lar Kit is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9351923 | Extended-release composition comprising a somatostatin derivative in microparticles |
23 May, 2028
(3 years from now)
| Active |
| US7473761 | Somatostatin analogues |
14 Dec, 2026
(1 year, 11 months from now)
| Active |
| US7759308 | Microparticles comprising somatostatin analogues |
25 Oct, 2026
(1 year, 10 months from now)
| Active |
| US8822637 | Somatostatin analogues |
06 Aug, 2023
(1 year, 4 months ago)
| Expired |
| US6225284 | Somatostatin peptides |
28 Jun, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Signifor Lar Kit's drug page